Literature DB >> 15217907

Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells.

Layton Harris Smith1, Stephen R Coats, Hao Qin, Matthew S Petrie, Joseph W Covington, Ming Su, Mesut Eren, Douglas E Vaughan.   

Abstract

To investigate the molecular mechanisms involved in the estrogen-dependent control of plasminogen activator inhibitor-1 (PAI-1) gene expression in vascular cells, we compared the transactivation properties of estrogen receptors (ERalpha and ERbeta) in regulating the activity of a human PAI-1 promoter reporter construct in transfected bovine aortic endothelial cells (BAECs). ERalpha increased PAI-1 promoter activity in BAECs by an estrogen-dependent mechanism, whereas ERbeta suppressed PAI-1 promoter activity by an estrogen-independent mechanism. The suppressive activity of ERbeta was dominant over the inductive activity of ERalpha. Mutation of a putative estrogen response element (ERE) located at position -427 in the proximal promoter abolished the ERalpha action without influencing the suppressive effects of ERbeta. Mutation of either AP1-like site did not eliminate the ERalpha or ERbeta actions at the PAI-1 promoter, suggesting that other promoter elements are involved in these responses. These mutations significantly reduced the -3.4kbp PAI-1 promoter response to serum. We concluded that ERalpha and ERbeta exert differential effects on the PAI-1 promoter activity in transfected BAECs. ERalpha activated the PAI-1 promoter through a proximal ERE (-427) and possibly additional EREs located within the PAI-1 promoter, whereas ERbeta suppressed the promoter construct via an unidentified mechanism. This is the first demonstration of the differential regulation of a vascular gene promoter by ERalpha and ERbeta.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217907     DOI: 10.1161/01.RES.0000136521.70093.f1

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

1.  Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model.

Authors:  Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 2.  Vascular effects of estrogenic menopausal hormone therapy.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Rev Recent Clin Trials       Date:  2012-02

3.  Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Brian T Pentecost; Nicole Lostritto; Neal A Englert; Geoffrey K Benn; Angela K Goodenough; Robert J Turesky; David C Spink
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-18       Impact factor: 4.219

4.  Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats.

Authors:  Vincent Ricchiuti; Christine G Lian; Eveline M Oestreicher; Loc Tran; James R Stone; Tham Yao; Ellen W Seely; Gordon H Williams; Gail K Adler
Journal:  J Endocrinol       Date:  2008-10-17       Impact factor: 4.286

5.  Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2.

Authors:  Seiji Tsutsumi; Xi Zhang; Keiko Takata; Kazuhiro Takahashi; Richard H Karas; Hirohisa Kurachi; Michael E Mendelsohn
Journal:  J Endocrinol       Date:  2008-08-27       Impact factor: 4.286

6.  Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.

Authors:  Elena E Tzekaki; George Geromichalos; Sophia N Lavrentiadou; Maria P Tsantarliotou; Anastasia A Pantazaki; Angelos Papaspyropoulos
Journal:  Breast Cancer Res Treat       Date:  2021-01-03       Impact factor: 4.872

7.  The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease.

Authors:  Monika Katko; Erika Galgoczi; Annamaria Erdei; Annamaria Gazdag; Eszter Berta; Miklos Bodor; Ildiko Seres; Ildiko Hircsu; Arpad Badics; Bernadett Ujhelyi; Livia Sira; Harjit Pal Bhattoa; Endre V Nagy
Journal:  J Inflamm Res       Date:  2021-05-12

8.  Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.

Authors:  Jessica M Grunda; Adam D Steg; Qinghua He; Mark R Steciuk; Suzanne Byan-Parker; Martin R Johnson; William E Grizzle
Journal:  BMC Res Notes       Date:  2012-05-22

9.  Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1.

Authors:  Anders E A Dahm; Nina Iversen; Baard Birkenes; Anne Hansen Ree; Per Morten Sandset
Journal:  BMC Cardiovasc Disord       Date:  2006-10-09       Impact factor: 2.298

10.  Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo.

Authors:  Jun Ming Wang; Ronald W Irwin; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.